This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Becton Dickinson (BDX), Agios Pharma (AGIO) and Healthequity (HQY)

Tipranks - Tipranks - Sat May 30, 11:56AM CDT

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Becton Dickinson (BDX), Agios Pharma (AGIO) and Healthequity (HQY).

Memorial Day Sale – Claim 70% Off TipRanks

Becton Dickinson (BDX)

In a report released today, Josh Jennings from TD Cowen reiterated a Hold rating on Becton Dickinson, with a price target of $163.00. The company’s shares closed last Friday at $148.71.

According to TipRanks.com, Jennings is a 3-star analyst with an average return of 0.7% and a 44.4% success rate. Jennings covers the Healthcare sector, focusing on stocks such as Anteris Technologies Global Corp., Establishment Labs Holdings, and Orchestra BioMed Holdings. ;'>

Currently, the analyst consensus on Becton Dickinson is a Moderate Buy with an average price target of $182.40, a 23.0% upside from current levels. In a report issued on May 27, Piper Sandler also maintained a Hold rating on the stock with a $161.00 price target.

See today’s best-performing stocks on TipRanks >>

Agios Pharma (AGIO)

H.C. Wainwright analyst Emily Bodnar maintained a Buy rating on Agios Pharma today and set a price target of $50.00. The company’s shares closed last Friday at $29.91, close to its 52-week low of $27.14.

According to TipRanks.com, Bodnar is a 4-star analyst with an average return of 7.4% and a 36.8% success rate. Bodnar covers the Healthcare sector, focusing on stocks such as First Tracks Biotherapeutics Inc, Artiva Biotherapeutics, Inc., and Acrivon Therapeutics, Inc. ;'>

Currently, the analyst consensus on Agios Pharma is a Moderate Buy with an average price target of $39.20, which is a 34.8% upside from current levels. In a report issued on May 22, Bank of America Securities also maintained a Buy rating on the stock with a $41.00 price target.

Healthequity (HQY)

Barrington analyst Alexander Paris reiterated a Buy rating on Healthequity today and set a price target of $110.00. The company’s shares closed last Friday at $87.74.

According to TipRanks.com, Paris is a 5-star analyst with an average return of 20.8% and a 65.9% success rate. Paris covers the Consumer Goods sector, focusing on stocks such as Phoenix Education Partners, Inc., Universal Technical Institute, and American Public Education. ;'>

Currently, the analyst consensus on Healthequity is a Strong Buy with an average price target of $114.27, representing a 24.9% upside. In a report released today, TipRanks – Anthropic also upgraded the stock to Buy with a $100.00 price target.

Read More on BDX:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).